180 Therapeutics LP

Oxford University Innovation Ltd

The Kennedy Trust for Rheumatology Research

Isis Innovation Limited

Jagdeep Nanchahal

Marc Feldmann

Glenn R Larsen

Kim Suzanne Midwood

Mervyn Maze

Mario Cibelli

Daqing Ma

Michael Fertleman

Niccolo Terrando

Noccolo Terrando

Glenn Larsen

The subject invention provides a method of treating an individual afflicted with early stage Dupuytren's disease characterized by the presence of one or more nodules on the individual's hand which comprises injecting into each nodule a pharmaceutical composition comprising an amount of an antihuman TNFa antibody or fragment thereof effective to treat the individual, wherein the pharmaceutical composition is in the form of a liquid and between 0.1 ml and 0.6 ml of the composition is injected into each nodule. This invention also provides for a pre-filled syringe for carrying out the above-described method.

Method of treating early stage Dupuytren's disease

The present invention provides method, uses and agents for preventing or reducing cognitive decline in a patient following a planned inflammatory trigger. Such planned inflammatory trigger can be a surgical procedure or chemotherapy. The invention further provides methods, uses and agents for reducing cognitive decline in a patient with a cognitive disorder, wherein said patient has been exposed to an inflammatory trigger. Pharmaceutical compositions and kits are also provided.

Methods for reducing post-operative cognitive dysfunction (POCD)

Method of treating dupuytren's disease using a pre-filled syringe

The subject invention provides a method of treating a patient suffering from a localized fibrotic condition which comprises administering to the patient an amount of an IL-33 antagonist effective to treat the patient. The subject invention also provides a method of treating a patient suffering from a localized fibrotic condition which comprises administering to the patient an amount of a TNF receptor 2 (TNFR2) antagonist effective to treat the patient.

Method of treating a localized fibrotic disorder using an IL-33 antagonist

Musculoskeletal fibroproliferative disorders, such as Dupuytren's disease may be treated by administering locally a TNF-&#x3b1; antagonist. TNF-&#x3b1; antagonists find particular utility in inhibiting the progression of early disease state Dupuytren's disease and other musculoskeletal fibroproliferative disorders and, in combination with extracellular matrix degradation agents (such as collagenase or matrix metalloproteinase I), treating advanced disease state Dupuytren's disease and, in particular inhibiting recurrence.

Treatment for Dupuytren's disease

Treatment for dupuytren's disease

Musculoskeletal fibroproliferative disorders, such as Dupuytren's disease may be treated by administering locally a TNF-&#x3b1; antagonist. TNF-&#x3b1; antagonists find particular utility in inhibiting the progression of early disease state Dupuytren's disease and other musculoskeletal fibroproliferative disorders and, in combination with extracellular matrix degradation agents (such ascollagenase or matrix metalloproteinase I), treating advanced disease state Dupuytren's disease and, in particular inhibiting recurrence.

Growing community of inventors

Headington, United Kingdom

Jagdeep Nanchahal